Clinical trial NCT00113204 - References

Multiple Myeloma — Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma

Citation(s)

•   Maloney A, Workman P
  HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther. 2002 Jan;2(1):3-24. Review.
•   Neckers L
  Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med. 2002;8(4 Suppl):S55-61. Review.
•   Pratt WB, Toft DO
  Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood). 2003 Feb;228(2):111-33. Review.

A Phase 1, Safety Assessment and Pharmacokinetic Study of IPI-504 in Patients With Relapsed, and Relapsed Refractory Multiple Myeloma

Details for clinical trial NCT00113204